Thursday 7 May, 2026
Introduction: Model-Informed Precision Dosing (MIPD) uses mathematical models to interpret therapeutic drug monitoring samples and predict personalized dosing strategies [1]….
Read morePoster: Methodology - Covariate/Variability Models
A logistic regression framework for predicting time‑varying vaccine efficacy using longitudinal immunogenicity data: a dengue vaccine case study
Thursday 7 May, 2026
Objectives: The durability of vaccine-induced protection and its variability across different demographic groups are key questions in vaccine development. Traditional…
Read moreBayesian population PK estimation of linear PK parameters of monoclonal AB with reusable priors for downstream applications.
Thursday 7 May, 2026
Introduction: Monoclonal antibodies (mABs) typically show linear PK which are consistent for the class, under target-absent conditions. It would be…
Read moreIMPLEMENTING A FULL RANDOM EFFECTS MODEL (FREM) WORKFLOW IN R USING THE SAEMIX PACKAGE
Thursday 7 May, 2026
Background: Covariate analysis remains a critical challenge in pharmacometrics. The Full Random Effects Model (FREM) [1] offers a robust solution…
Read moreComparison of an uncertainty-based dynamical SCM-ML approach with classical covariate model building techniques
Thursday 7 May, 2026
Objective Covariate model building (CMB) remains one of the most time-consuming and decision-intensive steps in population pharmacokinetic (popPK) modeling. Stepwise…
Read moreSIMULATION AND ESTIMATION OF CORRELATED NON-GAUSSIAN RANDOM EFFECTS IN PUMAS USING COPULAS
Thursday 7 May, 2026
Objectives: Nonlinear mixed-effects models typically assume multivariate normal random effects to describe inter-individual variability. In some applications, more flexible marginal…
Read moreTHE EFFECT OF COVARIATES ON TEMOZOLOMIDE EXPOSURE: A POPULATION PHARMACOKINETIC ANALYSIS APPROACH.
Thursday 7 May, 2026
Objectives Glioblastoma multiforme (GBM) is a poor prognosis cancer, with studies suggesting that only 4% of patients survive beyond five…
Read moreSEEING THE FOREST FOR THE TREES: FOREST PLOTS IN PHARMACOMETRICS
Thursday 7 May, 2026
Introduction: Forest plots (FPs) originate from the field of statistical meta-analysis to visualize individual study effects and overall pooled effects…
Read moreMissing data imputation for aggregate covariates of patient characteristics in model-based meta-analysis
Thursday 7 May, 2026
Objectives Model-based meta-analysis (MBMA) integrates data across clinical trials to estimate treatment effects. Including summary-level patient characteristics (covariates) can explain…
Read moreShould models for model-informed precision dosing (MIPD) purposes be full random-effects models (FREM) when a covariate is missing?
Thursday 7 May, 2026
Introduction: In clinical practice, missing covariate data (e.g., genetic test, stool biomarker) often limits the use of model-informed precision dosing…
Read more